Tailane Moreira - Academia.edu (original) (raw)
Uploads
Papers by Tailane Moreira
Introducao: A Farmacopeia Brasileira (FBras) tem o papel de garantir a autonomia nacional no esta... more Introducao: A Farmacopeia Brasileira (FBras) tem o papel de garantir a autonomia nacional no estabelecimento da qualidade minima dos medicamentos, insumos farmaceuticos e produtos para saude a serem comercializados no Brasil. A FBras nao tem laboratorio proprio e, por isso, parcerias sao firmadas com instituicoes publicas para que os complexos ensaios laboratoriais sejam realizados. O Laboratorio de Controle da Qualidade de Farmacos e Medicamentos da Faculdade de Farmacia da UFRJ (LabCQ – FF/UFRJ) atua desde 2000 como laboratorio colaborador da FBras no monitoramento e certificacao de Substâncias Quimicas de Referencia (SQRs) e revisao de monografias. As SQRs da FBras sao imprescindiveis na analise de medicamentos e abastecem os laboratorios fiscais de todo pais, bem como industrias farmaceuticas e Centros de Equivalencia Farmaceutica. O LabCQ estabeleceu um Convenio de Cooperacao com a FBras/ANVISA (TC 08/2010), com vigencia de 2010-2015, que preve recursos para bolsas de alunos de...
Introducao: O acesso da populacao aos medicamentos se da pela disponibilizacao atraves do SUS ou ... more Introducao: O acesso da populacao aos medicamentos se da pela disponibilizacao atraves do SUS ou da comercializacao por parte das industrias farmaceuticas. Para tanto, e necessario o registro do medicamento junto ao Ministerio da Saude. Uma das etapas necessarias para obtencao do registro e a analise de equivalencia farmaceutica junto a um laboratorio habilitado pela Agencia de Vigilância Sanitaria (ANVISA). A Faculdade de Farmacia da UFRJ (FF/UFRJ) possui o Laboratorio de Controle de Qualidade (CQ) de Farmacos e Medicamentos (LabCQ), habilitado pela ANVISA para analises de CQ e registro de medicamentos. Objetivos: O presente projeto visa a manutencao e ampliacao da participacao dos alunos de graduacao da FF/UFRJ na execucao das analises do LabCQ junto a ANVISA, atraves da ampliacao do escopo de atuacao para certificacao no Instituto Nacional de Metrologia (INMETRO) e Ministerio da Agricultura e Pecuaria (MAPA). Resultados: Como resultado desta habilitacao junto a ANVISA, os alunos ...
Macromolecular Symposia, 2014
Summary Tamoxifen (TXF) is a drug used as a hormonal agent for treatment of breast cancer. Due to... more Summary Tamoxifen (TXF) is a drug used as a hormonal agent for treatment of breast cancer. Due to its low solubility/bioavailability, the effectiveness of TXF can be improved when the drug is combined with drug delivery systems (DDS). For this reason, the in situ incorporation of TXF in polymer particles produced through miniemulsion polymerizations is studied here. Reactions were performed through standard free radical (FR) and RAFT polymerizations, using methyl methacrylate (MMA) as monomer and 2,2'-azobisisobutironitrila (AIBN) as initiator. It is shown that TXF can be incorporated successfully into the final polymer particles through miniemulsion polymerizations and that the presence of TXF in the reaction medium does not affect significantly the reaction rates, the particle size distribution and the molar mass distribution of the final polymer, even when the monomer feed contains 10 wt% of drug. Therefore, it is shown that DDS containing TXF can be produced by in situ miniemulsion FR and RAFT MMA polymerizations.
Polímeros Ciência e Tecnologia, 2014
Tamoxifen (TXF) is currently the only hormonal agent used for treatment of breast cancer. Althoug... more Tamoxifen (TXF) is currently the only hormonal agent used for treatment of breast cancer. Although very effective, TXF presents low solubility in water, which affects its absorption and bioavailability. A common strategy to overcome this barrier is the formulation of a drug delivery system (DDS) in order to increase the drug stability and improve the treatment effectiveness. Reversible addition-fragmentation chain transfer (RAFT) polymerization is the most versatile method of controlled/living radical polymerization (CLRP), allowing for synthesis of well-defined polymers and being adapted to a wide range of polymerization systems. Miniemulsion polymerization is a dispersed system that is commonly used to prepare nanoparticles (NP) with 50 to 500 nm of diameter. The aim of this work was to evaluate the effect of the in situ incorporation of TXF during miniemulsion conventional and RAFT polymerizations, using methyl methacrylate (MMA) as monomer. Although the in situ addition of TXF promoted a slight reduction of the reaction rate, it did not affect the final particle size distribution of the latex or the molecular weight control exerted by the RAFT agent. The obtained results suggest that in situ incorporation of TXF during the synthesis of polymer NP via RAFT polymerization allows for production of a polymer DDS for different uses, such as the breast cancer treatment.
ISRN Pharmaceutics, 2011
A high-performance liquid chromatographic (HPLC) and a ultraviolet (UV) methods were developed an... more A high-performance liquid chromatographic (HPLC) and a ultraviolet (UV) methods were developed and validated for the quantitative determination of Dexibuprofen (DI) in pharmaceutical dosage form. HPLC was carried out by reversed phase technique on a RP-18 column with a mobile phase composed of acetonitrile and 0.5% triethylamine (pH 7.5 adjusted with orthophosphoric acid (30 : 70, v/v)). UV method was performed with the λ max at 222.0 nm. Both the methods showed good linearity, reproducibility and precision. No spectral or chromatographic interferences from the tablet excipients were found in UV and HPLC. The method was successfully applied to commercial DEXIFEN tablets. Validation parameters such as linearity, precision, accuracy, and specificity were determined. The proposed method could be applicable for routine analysis of DI and monitoring of the quality of marketed drugs.
Química Nova, 2009
Recebido em 19/6/08; aceito em 13/1/09; publicado na web em 30/4/09 EXTRACTION AND PURIFICATION O... more Recebido em 19/6/08; aceito em 13/1/09; publicado na web em 30/4/09 EXTRACTION AND PURIFICATION OF SELECTIVES CICLOOXIGENASE-2 NONSTEROIDAL ANTIINFLAMMATORY DRUGS. Celecoxib (CB) and lumiracoxib (LM) are potent COX-2 inhibitors widely marketed for the treatment of rheumatoid arthritis and osteoarthritis. Nevertheless, it is difficult to obtain because it are protected under patents. The aim of this work was to develop an extraction method of drugs, CB and LM, in order to obtain the drug with a purity degree appropriated for use in research projects. The developed method showed to be effective of both drugs, becoming interesting due to its low cost, easy and speed of execution, application to different dosage forms (capsules and tablets) and drugs with different physicochemical properties.
Química Nova
... de Sistemas de Liberação Transdérmicos para o Antiinflamatório Lumiracoxibe: Obtenção, Avalia... more ... de Sistemas de Liberação Transdérmicos para o Antiinflamatório Lumiracoxibe: Obtenção, Avaliação Físico-Química e Estudos de Permeação in vitro em Pele de Modelo Animal, Universidade Federal do Rio de Janeiro, Brasil, 2008. [ Links ]. 13. Saha, RN; Sajeev, C.; Jadhav ...
AAPS PharmSciTech, 2010
Transdermal delivery of non-steroidal anti-inflammatory drugs may be an interesting strategy for ... more Transdermal delivery of non-steroidal anti-inflammatory drugs may be an interesting strategy for delivering these drugs to the diseased site, but it would be ineffective due to low skin permeability. We investigated whether oleic acid (OA), a lipid penetration enhancer in poloxamer gels named poloxamer-based delivery systems (PBDS), can improve lumiracoxib (LM) delivery to/through the skin. The LM partition coefficient (K) studies were carried out in order to evaluate the drug lipophilicity grade (K octanol/buffer), showing values >1 which demonstrated its high lipophilicity. Both in vitro percutaneous absorption and skin retention studies of LM were measured in the presence or absence of OA (in different concentrations) in PBDS using porcine ear skin. The flux of in vitro percutaneous absorption and in vitro retention of LM in viable epidermis increased in the presence of 10.0% (w/w) OA in 25.0% (w/w) poloxamer gel. In vivo cutaneous irritation potential was carried out in rabbits showing that this formulation did not provide primary or cumulative cutaneous irritability in animal model. The results showed that 25.0% poloxamer gel containing 10.0% OA is potential transdermal delivery system for LM.
Journal of Pharmacy & Pharmaceutical Sciences, 2010
PURPOSE: Transdermal delivery of anti-inflammatory lumiracoxib (LM) could be an interesting strat... more PURPOSE: Transdermal delivery of anti-inflammatory lumiracoxib (LM) could be an interesting strategy to avoid the side effects associated with systemic delivery, but it is ineffective due to the drug poor skin penetration. We have investigated the effects of oleic acid (OA), a lipid penetration enhancer, on the in vitro release of LM from poloxamer-based delivery systems (PBDS). The rheological behavior (shear rate dependent viscosity) and gelation temperature through measurements of optimal sol-gel transition temperatures (Tsol-gel) were also carried out in these systems. METHODS: In vitro release studies of LM from PBDS were performed using cellulose acetate as artificial membrane mounted in a diffusion system. The amount of LM released was divided by exposition area (µg/cm2) and these values were plotted as function of the time (h). The flux of the drug across the membrane (J) was calculated from the slope of the linear portion of the plot and expressed as µg/cm2. h -1. The deter...
Introducao: A Farmacopeia Brasileira (FBras) tem o papel de garantir a autonomia nacional no esta... more Introducao: A Farmacopeia Brasileira (FBras) tem o papel de garantir a autonomia nacional no estabelecimento da qualidade minima dos medicamentos, insumos farmaceuticos e produtos para saude a serem comercializados no Brasil. A FBras nao tem laboratorio proprio e, por isso, parcerias sao firmadas com instituicoes publicas para que os complexos ensaios laboratoriais sejam realizados. O Laboratorio de Controle da Qualidade de Farmacos e Medicamentos da Faculdade de Farmacia da UFRJ (LabCQ – FF/UFRJ) atua desde 2000 como laboratorio colaborador da FBras no monitoramento e certificacao de Substâncias Quimicas de Referencia (SQRs) e revisao de monografias. As SQRs da FBras sao imprescindiveis na analise de medicamentos e abastecem os laboratorios fiscais de todo pais, bem como industrias farmaceuticas e Centros de Equivalencia Farmaceutica. O LabCQ estabeleceu um Convenio de Cooperacao com a FBras/ANVISA (TC 08/2010), com vigencia de 2010-2015, que preve recursos para bolsas de alunos de...
Introducao: O acesso da populacao aos medicamentos se da pela disponibilizacao atraves do SUS ou ... more Introducao: O acesso da populacao aos medicamentos se da pela disponibilizacao atraves do SUS ou da comercializacao por parte das industrias farmaceuticas. Para tanto, e necessario o registro do medicamento junto ao Ministerio da Saude. Uma das etapas necessarias para obtencao do registro e a analise de equivalencia farmaceutica junto a um laboratorio habilitado pela Agencia de Vigilância Sanitaria (ANVISA). A Faculdade de Farmacia da UFRJ (FF/UFRJ) possui o Laboratorio de Controle de Qualidade (CQ) de Farmacos e Medicamentos (LabCQ), habilitado pela ANVISA para analises de CQ e registro de medicamentos. Objetivos: O presente projeto visa a manutencao e ampliacao da participacao dos alunos de graduacao da FF/UFRJ na execucao das analises do LabCQ junto a ANVISA, atraves da ampliacao do escopo de atuacao para certificacao no Instituto Nacional de Metrologia (INMETRO) e Ministerio da Agricultura e Pecuaria (MAPA). Resultados: Como resultado desta habilitacao junto a ANVISA, os alunos ...
Macromolecular Symposia, 2014
Summary Tamoxifen (TXF) is a drug used as a hormonal agent for treatment of breast cancer. Due to... more Summary Tamoxifen (TXF) is a drug used as a hormonal agent for treatment of breast cancer. Due to its low solubility/bioavailability, the effectiveness of TXF can be improved when the drug is combined with drug delivery systems (DDS). For this reason, the in situ incorporation of TXF in polymer particles produced through miniemulsion polymerizations is studied here. Reactions were performed through standard free radical (FR) and RAFT polymerizations, using methyl methacrylate (MMA) as monomer and 2,2'-azobisisobutironitrila (AIBN) as initiator. It is shown that TXF can be incorporated successfully into the final polymer particles through miniemulsion polymerizations and that the presence of TXF in the reaction medium does not affect significantly the reaction rates, the particle size distribution and the molar mass distribution of the final polymer, even when the monomer feed contains 10 wt% of drug. Therefore, it is shown that DDS containing TXF can be produced by in situ miniemulsion FR and RAFT MMA polymerizations.
Polímeros Ciência e Tecnologia, 2014
Tamoxifen (TXF) is currently the only hormonal agent used for treatment of breast cancer. Althoug... more Tamoxifen (TXF) is currently the only hormonal agent used for treatment of breast cancer. Although very effective, TXF presents low solubility in water, which affects its absorption and bioavailability. A common strategy to overcome this barrier is the formulation of a drug delivery system (DDS) in order to increase the drug stability and improve the treatment effectiveness. Reversible addition-fragmentation chain transfer (RAFT) polymerization is the most versatile method of controlled/living radical polymerization (CLRP), allowing for synthesis of well-defined polymers and being adapted to a wide range of polymerization systems. Miniemulsion polymerization is a dispersed system that is commonly used to prepare nanoparticles (NP) with 50 to 500 nm of diameter. The aim of this work was to evaluate the effect of the in situ incorporation of TXF during miniemulsion conventional and RAFT polymerizations, using methyl methacrylate (MMA) as monomer. Although the in situ addition of TXF promoted a slight reduction of the reaction rate, it did not affect the final particle size distribution of the latex or the molecular weight control exerted by the RAFT agent. The obtained results suggest that in situ incorporation of TXF during the synthesis of polymer NP via RAFT polymerization allows for production of a polymer DDS for different uses, such as the breast cancer treatment.
ISRN Pharmaceutics, 2011
A high-performance liquid chromatographic (HPLC) and a ultraviolet (UV) methods were developed an... more A high-performance liquid chromatographic (HPLC) and a ultraviolet (UV) methods were developed and validated for the quantitative determination of Dexibuprofen (DI) in pharmaceutical dosage form. HPLC was carried out by reversed phase technique on a RP-18 column with a mobile phase composed of acetonitrile and 0.5% triethylamine (pH 7.5 adjusted with orthophosphoric acid (30 : 70, v/v)). UV method was performed with the λ max at 222.0 nm. Both the methods showed good linearity, reproducibility and precision. No spectral or chromatographic interferences from the tablet excipients were found in UV and HPLC. The method was successfully applied to commercial DEXIFEN tablets. Validation parameters such as linearity, precision, accuracy, and specificity were determined. The proposed method could be applicable for routine analysis of DI and monitoring of the quality of marketed drugs.
Química Nova, 2009
Recebido em 19/6/08; aceito em 13/1/09; publicado na web em 30/4/09 EXTRACTION AND PURIFICATION O... more Recebido em 19/6/08; aceito em 13/1/09; publicado na web em 30/4/09 EXTRACTION AND PURIFICATION OF SELECTIVES CICLOOXIGENASE-2 NONSTEROIDAL ANTIINFLAMMATORY DRUGS. Celecoxib (CB) and lumiracoxib (LM) are potent COX-2 inhibitors widely marketed for the treatment of rheumatoid arthritis and osteoarthritis. Nevertheless, it is difficult to obtain because it are protected under patents. The aim of this work was to develop an extraction method of drugs, CB and LM, in order to obtain the drug with a purity degree appropriated for use in research projects. The developed method showed to be effective of both drugs, becoming interesting due to its low cost, easy and speed of execution, application to different dosage forms (capsules and tablets) and drugs with different physicochemical properties.
Química Nova
... de Sistemas de Liberação Transdérmicos para o Antiinflamatório Lumiracoxibe: Obtenção, Avalia... more ... de Sistemas de Liberação Transdérmicos para o Antiinflamatório Lumiracoxibe: Obtenção, Avaliação Físico-Química e Estudos de Permeação in vitro em Pele de Modelo Animal, Universidade Federal do Rio de Janeiro, Brasil, 2008. [ Links ]. 13. Saha, RN; Sajeev, C.; Jadhav ...
AAPS PharmSciTech, 2010
Transdermal delivery of non-steroidal anti-inflammatory drugs may be an interesting strategy for ... more Transdermal delivery of non-steroidal anti-inflammatory drugs may be an interesting strategy for delivering these drugs to the diseased site, but it would be ineffective due to low skin permeability. We investigated whether oleic acid (OA), a lipid penetration enhancer in poloxamer gels named poloxamer-based delivery systems (PBDS), can improve lumiracoxib (LM) delivery to/through the skin. The LM partition coefficient (K) studies were carried out in order to evaluate the drug lipophilicity grade (K octanol/buffer), showing values >1 which demonstrated its high lipophilicity. Both in vitro percutaneous absorption and skin retention studies of LM were measured in the presence or absence of OA (in different concentrations) in PBDS using porcine ear skin. The flux of in vitro percutaneous absorption and in vitro retention of LM in viable epidermis increased in the presence of 10.0% (w/w) OA in 25.0% (w/w) poloxamer gel. In vivo cutaneous irritation potential was carried out in rabbits showing that this formulation did not provide primary or cumulative cutaneous irritability in animal model. The results showed that 25.0% poloxamer gel containing 10.0% OA is potential transdermal delivery system for LM.
Journal of Pharmacy & Pharmaceutical Sciences, 2010
PURPOSE: Transdermal delivery of anti-inflammatory lumiracoxib (LM) could be an interesting strat... more PURPOSE: Transdermal delivery of anti-inflammatory lumiracoxib (LM) could be an interesting strategy to avoid the side effects associated with systemic delivery, but it is ineffective due to the drug poor skin penetration. We have investigated the effects of oleic acid (OA), a lipid penetration enhancer, on the in vitro release of LM from poloxamer-based delivery systems (PBDS). The rheological behavior (shear rate dependent viscosity) and gelation temperature through measurements of optimal sol-gel transition temperatures (Tsol-gel) were also carried out in these systems. METHODS: In vitro release studies of LM from PBDS were performed using cellulose acetate as artificial membrane mounted in a diffusion system. The amount of LM released was divided by exposition area (µg/cm2) and these values were plotted as function of the time (h). The flux of the drug across the membrane (J) was calculated from the slope of the linear portion of the plot and expressed as µg/cm2. h -1. The deter...